Cell Therapeutics (CTIC +10.9%) rallies after the FDA says the company's drug pixantrone, which...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor

Cell Therapeutics (CTIC +10.9%) rallies after the FDA says the company's drug pixantrone, which is under review for adults with non-Hodgkin's lymphoma, will be discussed by an advisory committee in early February.